The current paper strengthens the view that the IGF pathway can be an effective target for therapy in osteosarcoma, thereby emphasizing the need for the industrial facilitation of clinical trials with IGF-1R/insulin receptor dual inhibitors combined with chemotherapy, in which a strong translational program is embedded for predictive biomarker identification in osteosarcoma patients. This evidence concerns the gene INSR and osteosarcoma.